A Systematic Review and Meta-Analysis: Safety and Efficacy of Cediranib in the Treatment of Cancer Patients

Table 1

Baseline characteristics of included studies in the meta-analysis.

First author, year	Phase	Underlying malignancy	Treatment arm	Control arm	Patient enrolled	Age (years), median (range)	Median PFS (m)	Median OS (m)
Goss 2009	II	NSCLC	Cediranib 30 mg once daily plus PC	Placebo plus PC	251	Intervention: 60 (36–77)	0.77	—
						Control: 58 (39–81)
Kato 2011	II	CRC	Cediranib 20 mg once daily plus mFOLFOX6	Placebo plus mFOLFOX6	172	Intervention: 64 (33–79)	0.70	—
						Control: 64 (36–80)
Hoff 2012	III	CRC	Cediranib 20 mg once daily plus FOLFOX/CAPOX	Placebo plus FOLFOX/CAPOX	860	Intervention: 58 (22–83)	0.84	0.94
						Control: 59 (22–82)
Mulders 2012	II	RCC	Cediranib 45 mg once daily	Placebo	71	Intervention: 60 (46–75)	0.45	—
						Control: 61 (45–79)
Schmoll 2012	III	CRC	Cediranib 20 mg once daily plus mFOLFOX6	Bevacizumab plus mFOLFOX6	1422	Intervention: 59 (18–83)	1.10	0.95
						Control: 60 (22–88)
Dy 2013	II	NSCLC	Cediranib 30 mg once daily plus GC	GC	87	Intervention: 65 (46–81)	0.69	0.66
						Control: 64 (45–82)
Hyams 2013	II	BC	Cediranib 45 mg once daily plus fulvestrant	Placebo plus fulvestrant	62	59 (18–83)	0.867	—
Batchelor 2013	III	GB	Cediranib 20 mg once daily plus lomustine	Placebo plus lomustine	325	Intervention: 54	0.76	1.15
						Control: 54
Laurie 2014	III	NSCLC	Cediranib 20 mg once daily plus PC	Placebo plus PC	306	Intervention: 63 (23–85)	0.91	0.94
						Control: 62 (36–77)
Symonds 2015	II	CC	Cediranib 20 mg once daily plus PC	Placebo plus PC	69	Intervention: 44 (37–60)	0.58	—
						Control: 44 (34–53)
Valle 2015	II	BTC	Cediranib 20 mg once daily plus GP	Placebo plus GP	124	Intervention: 68 (60–73)	0.93	0.86
						Control: 64.5 (60–73)
Tsao 2019	II	MPM	Cediranib plus PP	Placebo plus PP	92	Intervention: 72 (46–82)	0.77	0.88
						Control: 72 (51–85)
Liu 2019	II	OC	Cediranib 30 mg once daily plus olaparib	Olaparib	90	Intervention: 58 (53–67)	0.5	0.64
						Control: 58 (52–63)
Lederman 2021	III	OC	Cediranib 20 mg once daily plus PC	Placebo plus PC	456	Intervention: 62 (54–68)	0.56	0.86
						Control: 62 (53–67)

Abbreviations: NSCLC: nonsmall cell lung cancer; CRC: colorectal cancer; RCC: renal cell carcinoma; BC: breast cancer; GB: glioblastoma; CC: cervical cancer; BTC: biliary tract cancer; MPM: malignant pleural mesothelioma; OC: ovarian cancer; PC: paclitaxel-carboplatin; mFOLFOX6: modified FOLFOX6; FOLFOX/CAPOX: fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin; GC: gemcitabine-carboplatin; GP: gemcitabine-cisplatin; PP: pemetrexed-platinum; m: months.